Deutsch English Français

Contact

EP3265483

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...

News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...

Extract from the Register of European Patents

EP About this file: EP3265483

EP3265483 - MODIFIED VON WILLEBRAND FACTOR HAVING IMPROVED HALF-LIFE [Right-click to bookmark this link]
Status	No opposition filed within time limit Status updated on 16.10.2020 Database last updated on 22.05.2024
Former	The patent has been granted Status updated on 08.11.2019
Former	Grant of patent is intended Status updated on 27.06.2019
Former	Examination is in progress Status updated on 16.11.2018
Former	Request for examination was made Status updated on 08.12.2017
Former	The international publication has been made Status updated on 07.10.2017
Most recent event Tooltip	08.07.2022	Lapse of the patent in a contracting state New state(s): MK	published on 10.08.2022 [2022/32]
Applicant(s)	For all designated states CSL Behring Lengnau AG Industriestrasse 11 2543 Lengnau BE / CH
	[2018/43]
Former [2018/02]	For all designated states CSL Behring Recombinant Facility AG Wankdorfstrasse 10 3014 Bern / CH
Inventor(s)	01 / MOSES, Michael Am Feldweg 11 61279 Graevenwiesbach / DE
	02 / SCHULTE, Stefan Bauerbacher Strasse 46 35043 Marburg / DE
	03 / DICKNEITE, Gerhard Zum Neuen Hieb 31 35043 Marburg / DE
	04 / KALINA, Uwe Ringstrasse 22 a 35041 Marburg / DE
	05 / PESTEL, Sabine Stuempelstal 19 35041 Marburg / DE
	06 / WEIMER, Thomas Richard-Wagner-Strasse 8 35075 Gladenbach / DE
	[2018/02]
Representative(s)	Ludwig, Holger, et al CSL Behring AG Wankdorfstrasse 10 3014 Bern / CH
	[N/P]
Former [2018/02]	Ludwig, Holger, et al CSL Behring GmbH Emil-von-Behring-Straße 76 35041 Marburg / DE
Application number, filing date	16712738.0	04.03.2016
	[2018/02]
	WO2016EP54647
Priority number, date	EP20150158065	06.03.2015 Original published format: EP 15158065
	[2018/02]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2016142288
	Date:	15.09.2016
	Language:	EN
	[2016/37]
	Type:	A1 Application with search report
	No.:	EP3265483
	Date:	10.01.2018
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 15.09.2016 takes the place of the publication of the European patent application.
	[2018/02]
	Type:	B1 Patent specification
	No.:	EP3265483
	Date:	11.12.2019
	Language:	EN
	[2019/50]
Search report(s)	International search report - published on:	EP	15.09.2016
Classification	IPC:	C07K14/755	[2018/02]
	CPC:	C07K14/755 (EP,CN,KR,US); A61K38/36 (KR); A61K38/37 (KR); A61P43/00 (EP,US); A61P7/04 (EP,US); A61K38/00 (CN)
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2018/02]
Extension states	BA	Not yet paid
	ME	Not yet paid
Validation states	MA	Not yet paid
	MD	Not yet paid
Title	German:	MODIFIZIERTER VON-WILLEBRAND-FAKTOR MIT VERBESSERTER HALBWERTZEIT	[2018/02]
	English:	MODIFIED VON WILLEBRAND FACTOR HAVING IMPROVED HALF-LIFE	[2018/02]
	French:	FACTEUR DE VON WILLEBRAND MODIFIÉ PRÉSENTANT UNE DEMI-VIE AMÉLIORÉE	[2019/27]
	Former [2018/02]	FACTEUR VON WILLEBRAND MODIFIÉ PRÉSENTANT UNE DEMI-VIE AMÉLIORÉE
Entry into regional phase	06.10.2017	National basic fee paid
	06.10.2017	Designation fee(s) paid
	06.10.2017	Examination fee paid
Examination procedure	06.10.2017	Examination requested [2018/02]
	06.10.2017	Date on which the examining division has become responsible
	03.05.2018	Amendment by applicant (claims and/or description)
	20.11.2018	Despatch of a communication from the examining division (Time limit: M04)
	21.03.2019	Reply to a communication from the examining division
	28.06.2019	Communication of intention to grant the patent
	28.10.2019	Fee for grant paid
	28.10.2019	Fee for publishing/printing paid
	28.10.2019	Receipt of the translation of the claim(s)
Opposition(s)	14.09.2020	No opposition filed within time limit [2020/47]
Fees paid	Renewal fee
	03.04.2018	Renewal fee patent year 03
	01.04.2019	Renewal fee patent year 04
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition Tooltip	HU	04.03.2016
	AL	11.12.2019
	AT	11.12.2019
	CY	11.12.2019
	CZ	11.12.2019
	EE	11.12.2019
	FI	11.12.2019
	HR	11.12.2019
	LT	11.12.2019
	LV	11.12.2019
	MC	11.12.2019
	MK	11.12.2019
	MT	11.12.2019
	PL	11.12.2019
	RO	11.12.2019
	RS	11.12.2019
	SI	11.12.2019
	SK	11.12.2019
	SM	11.12.2019
	TR	11.12.2019
	IE	04.03.2020
	LU	04.03.2020
	BG	11.03.2020
	NO	11.03.2020
	GR	12.03.2020
	BE	31.03.2020
	IS	11.04.2020
	PT	06.05.2020
	[2022/32]
Former [2022/27]	HU	04.03.2016
	AL	11.12.2019
	AT	11.12.2019
	CY	11.12.2019
	CZ	11.12.2019
	EE	11.12.2019
	FI	11.12.2019
	HR	11.12.2019
	LT	11.12.2019
	LV	11.12.2019
	MC	11.12.2019
	MT	11.12.2019
	PL	11.12.2019
	RO	11.12.2019
	RS	11.12.2019
	SI	11.12.2019
	SK	11.12.2019
	SM	11.12.2019
	TR	11.12.2019
	IE	04.03.2020
	LU	04.03.2020
	BG	11.03.2020
	NO	11.03.2020
	GR	12.03.2020
	BE	31.03.2020
	IS	11.04.2020
	PT	06.05.2020
Former [2021/13]	AL	11.12.2019
	AT	11.12.2019
	CZ	11.12.2019
	EE	11.12.2019
	FI	11.12.2019
	HR	11.12.2019
	LT	11.12.2019
	LV	11.12.2019
	MC	11.12.2019
	PL	11.12.2019
	RO	11.12.2019
	RS	11.12.2019
	SI	11.12.2019
	SK	11.12.2019
	SM	11.12.2019
	IE	04.03.2020
	LU	04.03.2020
	BG	11.03.2020
	NO	11.03.2020
	GR	12.03.2020
	BE	31.03.2020
	IS	11.04.2020
	PT	06.05.2020
Former [2021/08]	AL	11.12.2019
	AT	11.12.2019
	CZ	11.12.2019
	EE	11.12.2019
	FI	11.12.2019
	HR	11.12.2019
	LT	11.12.2019
	LV	11.12.2019
	MC	11.12.2019
	RO	11.12.2019
	RS	11.12.2019
	SI	11.12.2019
	SK	11.12.2019
	SM	11.12.2019
	IE	04.03.2020
	LU	04.03.2020
	BG	11.03.2020
	NO	11.03.2020
	GR	12.03.2020
	IS	11.04.2020
	PT	06.05.2020
Former [2021/04]	AL	11.12.2019
	AT	11.12.2019
	CZ	11.12.2019
	EE	11.12.2019
	FI	11.12.2019
	HR	11.12.2019
	LT	11.12.2019
	LV	11.12.2019
	MC	11.12.2019
	RO	11.12.2019
	RS	11.12.2019
	SI	11.12.2019
	SK	11.12.2019
	SM	11.12.2019
	LU	04.03.2020
	BG	11.03.2020
	NO	11.03.2020
	GR	12.03.2020
	IS	11.04.2020
	PT	06.05.2020
Former [2020/50]	AL	11.12.2019
	AT	11.12.2019
	CZ	11.12.2019
	EE	11.12.2019
	FI	11.12.2019
	HR	11.12.2019
	LT	11.12.2019
	LV	11.12.2019
	MC	11.12.2019
	RO	11.12.2019
	RS	11.12.2019
	SI	11.12.2019
	SK	11.12.2019
	SM	11.12.2019
	BG	11.03.2020
	NO	11.03.2020
	GR	12.03.2020
	IS	11.04.2020
	PT	06.05.2020
Former [2020/40]	AL	11.12.2019
	CZ	11.12.2019
	EE	11.12.2019
	FI	11.12.2019
	HR	11.12.2019
	LT	11.12.2019
	LV	11.12.2019
	RO	11.12.2019
	RS	11.12.2019
	SK	11.12.2019
	SM	11.12.2019
	BG	11.03.2020
	NO	11.03.2020
	GR	12.03.2020
	IS	11.04.2020
	PT	06.05.2020
Former [2020/37]	AL	11.12.2019
	CZ	11.12.2019
	EE	11.12.2019
	FI	11.12.2019
	HR	11.12.2019
	LT	11.12.2019
	LV	11.12.2019
	RO	11.12.2019
	RS	11.12.2019
	SK	11.12.2019
	SM	11.12.2019
	BG	11.03.2020
	NO	11.03.2020
	GR	12.03.2020
	PT	06.05.2020
Former [2020/36]	AL	11.12.2019
	CZ	11.12.2019
	EE	11.12.2019
	FI	11.12.2019
	HR	11.12.2019
	LT	11.12.2019
	LV	11.12.2019
	RO	11.12.2019
	RS	11.12.2019
	BG	11.03.2020
	NO	11.03.2020
	GR	12.03.2020
	PT	06.05.2020
Former [2020/35]	AL	11.12.2019
	CZ	11.12.2019
	FI	11.12.2019
	HR	11.12.2019
	LT	11.12.2019
	LV	11.12.2019
	RO	11.12.2019
	RS	11.12.2019
	BG	11.03.2020
	NO	11.03.2020
	GR	12.03.2020
Former [2020/32]	AL	11.12.2019
	FI	11.12.2019
	HR	11.12.2019
	LT	11.12.2019
	LV	11.12.2019
	RS	11.12.2019
	BG	11.03.2020
	NO	11.03.2020
	GR	12.03.2020
Former [2020/25]	FI	11.12.2019
	HR	11.12.2019
	LT	11.12.2019
	LV	11.12.2019
	RS	11.12.2019
	BG	11.03.2020
	NO	11.03.2020
	GR	12.03.2020
Former [2020/23]	FI	11.12.2019
	LT	11.12.2019
	LV	11.12.2019
	BG	11.03.2020
	NO	11.03.2020
	GR	12.03.2020
Former [2020/22]	FI	11.12.2019
	LT	11.12.2019
	BG	11.03.2020
	NO	11.03.2020
Former [2020/21]	NO	11.03.2020
Cited in	International search	[A]WO2013167303 (CSL BEHRING GMBH [DE]) [A] 1-19 * page 7, lines 4-12, 18-19 * * page 17, lines 4-8 *;
		[X] - IDINATH BADIROU ET AL, "In Vivo Analysis of the Role of O-Glycosylations of Von Willebrand Factor", PLOS ONE, (20120517), vol. 7, no. 5, doi:10.1371/journal.pone.0037508, page e37508, XP055202888 [X] 1-9,14 * figures 2-3, 5; table 1 * DOI: http://dx.doi.org/10.1371/journal.pone.0037508
		[X] - "SubName: Full=von Willebrand factor {ECO:0000313\|EMBL:KFV73032.1}; Flags: Fragment;", UniProt, (20141126), Database accession no. A0A093H1R9, URL: EBI, XP002742402 [X] 1-9,14 * sequence . *
		[A] - K. CANIS ET AL, "The plasma von Willebrand factor O -glycome comprises a surprising variety of structures including ABH antigens and disialosyl motifs", JOURNAL OF THROMBOSIS AND HAEMOSTASIS, (20100101), vol. 8, no. 1, doi:10.1111/j.1538-7836.2009.03665.x, ISSN 1538-7933, pages 137 - 145, XP055202964 [A] 1-19 * page 144, column l, paragraph 3; figure 5 * DOI: http://dx.doi.org/10.1111/j.1538-7836.2009.03665.x
		[A] - C. CASARI ET AL, "Clearance of von Willebrand factor", JOURNAL OF THROMBOSIS AND HAEMOSTASIS, (20130630), vol. 11, doi:10.1111/jth.12226, ISSN 1538-7933, pages 202 - 211, XP055202972 [A] 1-19 * page 204, column l, paragraph 4 - page 205, column r, paragraph 2; figure 2 * DOI: http://dx.doi.org/10.1111/jth.12226
		[A] - "SubName: Full=von Willebrand Factor like 1 {ECO:0000313\|EMBL:BAD05118.1}; Flags: Fragment;", UniProt, (20040705), Database accession no. Q769I3, URL: EBI, XP002742403 [A] 1-19 * sequence . *
	by applicant	WO8601533
		EP0392745
		US4970300
		US5219996
		WO9415625
		WO9703193
		WO9711957
		WO9740145
		EP0948544
		WO9955306
		WO02060951
		WO02103024
		WO03031464
		WO03087355
		WO03093313
		WO2004067566
		WO2004075923
		WO2004101740
		WO2005117984
		WO2005123780
		WO2006053299
		WO2006071801
		WO2006108590
		WO2007126808
		US2007280931
		WO2008077616
		WO2008082669
		WO2008135501
		WO2009007451
		WO2009062100
		WO2009108806
		WO2009156137
		WO2010014708
		WO2010045568
		US2010113365
		US2010113364
		US2010168391
		US2010173831
		US2010173830
		WO2010102886
		WO2010115866
		WO2011101242
		WO2011101284
		WO2011101277
		WO2011101267
		WO2011131510
		WO2012007324
		WO2013083858
		- COLLINS ET AL., PROC NATL. ACAD. SCI. USA, (1987), vol. 84, pages 4393 - 4397
		- FISCHER ET AL., FEBS LETT, (1994), vol. 351, pages 345 - 348
		- CANIS ET AL., JOURNAL OF THROMBOSIS AND HAEMOSTASIS, (2010), vol. 8, pages 137 - 145
		- CANIS ET AL., THE BIOCHEMICAL JOURNAL, (2012), vol. 447, pages 217 - 228
		- ZHOU ET AL., BLOOD, (2012), vol. 120, no. 2, pages 449 - 458
		- FEDERICI A B ET AL., HAEMATOLOGICA, (2004), vol. 89, pages 77 - 85
		- SUCKER ET AL., CLIN APPL THROMB HEMOST, (2006), vol. 12, pages 305 - 310
		- KALLAS; TALPSEP, ANNALS OF HEMATOLOGY, (2001), vol. 80, pages 466 - 471
		- VEYRADIER ET AL., HAEMOPHILIA, (2011), vol. 17, pages 944 - 951
		- BENDETOWICZ ET AL., BLOOD, (1998), vol. 92, no. 2, pages 529 - 538
		- "An Effect of Predilution on Potency Assays of FVIII Concentrates", N LEE; MARTIN L ET AL., Thrombosis Research, PERGAMON PRESS LTD., vol. 30, pages 511 - 519
		- WAHL ET AL., J. NUCL. MED, (1983), vol. 24, page 316
		- MORRISON, SCIENCE, (1985), vol. 229, no. 4719, pages 1202 - 1207
		- OI ET AL., BIOTECHNIQUES, (1986), vol. 4, pages 214 - 221
		- GILLIES ET AL., J. IMMUNOL. METHODS, (1985), vol. 125, pages 191 - 202
		- RIECHMANN ET AL., NATURE, (1988), vol. 332, pages 323 - 327
	- PADLAN, MOL. IMMUNOL, (1991), vol. 28, pages 489 - 498
	- STUDNICKA ET AL., PROT. ENG., (1994), vol. 7, pages 805 - 814
	- ROGUSKA ET AL., PROC. NATL. ACAD. SCI., (1994), vol. 91, pages 969 - 973
	- JESPERS ET AL., BIOTECHNOLOGY, (1988), vol. 12, pages 899 - 903
	- CANFIELD; MORRISON, J. EXP. MED., (1991), vol. 173, pages 1483 - 1491
	- LUND ET AL., J. IMMUNOL., (1991), vol. 147, pages 2657 - 2662
	- HELLSTROM, Controlled Drag Delivery, (1987), pages 623 - 653
	- THORPE, IMMUNOL. REV., (1982), vol. 62, pages 119 - 158
	- DUBOWCHIK, PHARMACOLOGY AND THERAPEUTICS, (1999), vol. 83, pages 67 - 123
	- CHAPMAN, ADVANCED DRUG DELIVERY REVIEWS, (2002), vol. 54, pages 531 - 545
	- Current Protocols in Molecular Biology, JOHN WILEY & SONS, INC.

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.1.24; 34p